See more : Halo Food Co. Limited (HLF.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Scilex Holding Company (SCLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scilex Holding Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Nihonwasou Holdings, Inc. (2499.T) Income Statement Analysis – Financial Results
- Qingdao Copton Technology Company Limited (603798.SS) Income Statement Analysis – Financial Results
- Campbell Soup Company (0HST.L) Income Statement Analysis – Financial Results
- Atul Ltd (ATUL.NS) Income Statement Analysis – Financial Results
- Toami Corporation (5973.T) Income Statement Analysis – Financial Results
Scilex Holding Company (SCLX)
About Scilex Holding Company
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 46.74M | 38.03M | 31.32M | 23.56M | 21.03M |
| Cost of Revenue | 15.68M | 10.80M | 3.63M | 2.15M | 5.80M |
| Gross Profit | 31.06M | 27.24M | 27.68M | 21.41M | 15.23M |
| Gross Profit Ratio | 66.45% | 71.61% | 88.40% | 90.88% | 72.41% |
| Research & Development | 12.75M | 9.05M | 9.20M | 9.96M | 85.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 119.64M | 64.90M | 50.58M | 42.97M | 64.70M |
| Other Expenses | 4.11M | 3.92M | 3.74M | 3.74M | 3.71M |
| Operating Expenses | 136.49M | 77.87M | 63.52M | 56.67M | 153.93M |
| Cost & Expenses | 152.17M | 88.67M | 67.16M | 58.82M | 159.73M |
| Interest Income | 0.00 | 9.60M | 11.76M | 13.12M | 460.00K |
| Interest Expense | 1.07M | 9.60M | 39.76M | 13.12M | 16.89M |
| Depreciation & Amortization | 4.15M | 4.45M | 4.15M | 3.78M | 3.75M |
| EBITDA | -109.10M | -9.30M | -44.88M | -31.48M | -134.49M |
| EBITDA Ratio | -233.41% | -122.71% | -102.37% | -133.62% | -639.40% |
| Operating Income | -105.43M | -50.63M | -35.84M | -35.26M | -138.70M |
| Operating Income Ratio | -225.55% | -133.13% | -114.44% | -149.65% | -659.42% |
| Total Other Income/Expenses | -8.89M | 27.27M | -52.58M | -12.31M | -39.90M |
| Income Before Tax | -114.32M | -23.36M | -88.42M | -47.57M | -178.59M |
| Income Before Tax Ratio | -244.57% | -61.42% | -282.34% | -201.92% | -849.10% |
| Income Tax Expense | 13.00K | 4.00K | 5.00K | -53.00K | 2.00K |
| Net Income | -114.33M | -23.36M | -88.42M | -47.52M | -178.59M |
| Net Income Ratio | -244.59% | -61.43% | -282.35% | -201.69% | -849.11% |
| EPS | -1.28 | -0.17 | -0.67 | -0.34 | -1.27 |
| EPS Diluted | -1.28 | -0.17 | -0.67 | -0.34 | -1.27 |
| Weighted Avg Shares Out | 130.30M | 134.23M | 132.86M | 141.10M | 141.10M |
| Weighted Avg Shares Out (Dil) | 130.30M | 134.23M | 132.86M | 141.10M | 141.10M |
Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®
PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.
PALO ALTO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company
PALO ALTO, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index
Has the potential to Enhance the visibility of Scilex's Non-Opioid Pain Management Therapeutics In Global Financial Markets Has the potential to Enhance the visibility of Scilex's Non-Opioid Pain Management Therapeutics In Global Financial Markets
Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company
PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Sorrento Therapeutics (OTCMKTS:SRNEQ) and bluebird bio (NASDAQ:BLUE) Financial Comparison
Sorrento Therapeutics (OTCMKTS:SRNEQ – Get Free Report) and bluebird bio (NASDAQ:BLUE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst...
Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
PALO ALTO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Source: https://incomestatements.info
Category: Stock Reports